Figure 3
![Figure 3. JS-K overcomes the protective effects of IL-6 and IGF-1, and adherence to patient BMSCs. MM.1S cells were treated for 48 hours with JS-K (0–2.4 μM) in the absence (□) or presence (■) of IL-6 (10 ng/mL) (A) or IGF-1 (50 ng/mL) (B), and without (□) or with BMSCs derived from MM patients 1(■) and 2 (□) (C). DNA synthesis was determined by measuring [3H]-thymidine incorporation during the last 8 hours of 48-hour cultures. Data represent means (± SD) of triplicate experiments.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/2/10.1182_blood-2006-10-052845/4/zh80130703370003.jpeg?Expires=1735496576&Signature=lj7qZd9tJMxavZGTT56SbVuNYPgo-HMZ46Edc~-i4KEMWaR~BO9bv6YqJBAk6Uzkbs-Y-djMph~r1v11e8u0F~08PZzHBmATcZwo0JPCb-55ZNOo5uDtTpyUgB1dzpTiIyh1ILL5PR0lDyRz-2pz~pI5ket4x5Nmd5jim7grf5pVccnLuAzeN8UHxHOPHWGkcacyj3DrPwJxl9K7kVC1jdOrJ42grHOOFN6DcQxor-Pp9ZPHdzd4KZJK~fTrjCtiCtwCBvOSVblptiM57rKdZysGg7R0eJ2I0WQBkrxEBWhnxfjOTplEwoHSzi5tdNN8gShjRkjshfBeXf1f8pVJ3Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
JS-K overcomes the protective effects of IL-6 and IGF-1, and adherence to patient BMSCs. MM.1S cells were treated for 48 hours with JS-K (0–2.4 μM) in the absence (□) or presence (■) of IL-6 (10 ng/mL) (A) or IGF-1 (50 ng/mL) (B), and without (□) or with BMSCs derived from MM patients 1(■) and 2 (□) (C). DNA synthesis was determined by measuring [3H]-thymidine incorporation during the last 8 hours of 48-hour cultures. Data represent means (± SD) of triplicate experiments.
